MedPath

Kidney Disease and Pulmonary Hypertension

Completed
Conditions
Pulmonary Hypertension
Registration Number
NCT03045614
Lead Sponsor
University of Giessen
Brief Summary

Evaluation of the prevalence of kidney disease, hemodynamic predictors and long-term renal outcome in patients with invasively diagnosed pulmonary hypertension.

Detailed Description

This study aims to determine the prevalence of kidney disease, hemodynamic predictors and long-term renal outcome of in-hospital patients with invasively diagnosed pulmonary hypertension at the Department of Pulmonology, University Hospital Giessen and Marburg, Giessen, Germany between 1999 and 2016.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
824
Inclusion Criteria
  • older than 18 years
  • subjects with invasively diagnosed pulmonary hypertension at rest and available renal function and spot urine data at day of right heart catheterization between March 1999 and December 2016 at the Department of Pulmonology, University Hospital Giessen and Marburg, Giessen, Germany
Exclusion Criteria
  • subjects with estimated GFR <15ml/min/1.73m2 or prior dialysis
  • pre-existing acute kidney injury
  • non-end stage renal disease with extracorporeal or peritoneal ultrafiltration due to diuretic-resistant fluid overload
  • primary kidney disease requiring active immunosuppression
  • autosomal dominant polycystic kidney disease
  • if subjects are pregnant
  • if subjects are recipients of solid-organ transplants
  • subjects with pulmonary hypertension with unclear/multifactorial mechanisms (WHO group 5 pulmonary hypertension)

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Changes in estimated glomerular filtration rate (GFR) in each class of pulmonary hypertension during follow-up period3 years follow-up

Estimated GFR (Chronic Kidney Disease Epidemiology Collaboration) will be used over follow-up period to determine changes in renal function

Impact of renal function on deterioration of pulmonary hypertension during follow-up period3 years follow-up

Changes in estimated GFR (Chronic Kidney Disease Epidemiology Collaboration) over follow-up period will be correlated with clinical worsening of pulmonary hypertension (as determined by echocardiography, 6-minute-walk, New York Heart Association classification, b-type natriuretic peptide)

Secondary Outcome Measures
NameTimeMethod
Impact of pulmonary hypertension-related morbidity on renal function decline3 years follow-up

Severity of pulmonary hypertension (progress pulmonary hypertension, unscheduled hospitalization due to worsening of pulmonary hypertension, mortality) will be correlated with changes in renal function (as determined by estimated GFR \[Chronic Kidney Disease Epidemiology Collaboration\])

Impact of pulmonary hypertension-specific therapy on renal function decline3 years follow-up

Estimated GFR (Chronic Kidney Disease Epidemiology Collaboration) over follow-up period will be assessed to show association of pulmonary hypertension-specific therapy on renal function

Prevalence of proteinuria in pulmonary hypertensionAt baseline

24 hours urine collection at baseline will be assessed to predict progress of pulmonary hypertension

Trial Locations

Locations (1)

University Clinic Giessen and Marburg - Campus Giessen

🇩🇪

Giessen, Hessen, Germany

© Copyright 2025. All Rights Reserved by MedPath